From Our Partners
Wednesday, July 6, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

Phase 1 Trial Begins for IV Version of Smallpox Drug

by Global Biodefense Staff
March 23, 2016
Biodefense Medical Countermeasures

Biodefense Medical CountermeasuresBacked by funding from the Biomedical Advanced Research and Development Authority (BARDA), SIGA Technologies is initiating a Phase I single ascending dose clinical study for the intravenous formulation of the TPOXX (tecovirimat) for the treatment of orthopoxvirus disease, including smallpox.

The oral version of the novel small-molecule drug is being delivered to the Strategic National Stockpile under Project BioShield. SIGA is developing the IV formulation as an alternative treatment for those individuals who suffer from dysphagia or seriously ill individuals who are hospitalized and cannot swallow oral capsules.

Screening of subjects began on March 7, 2016 and the first subject was expected to be enrolled and dosed on March 21, 2016. This study will evaluate safety data as well as pharmacokinetic data to aid in the development of a protocol for the next Phase I clinical trial in the IV program, a multiple ascending dose safety and pharmacokinetic trial.

“This collaboration with BARDA on an IV formulation is an important step toward realizing the full capability of TPOXX,” said Dr. Eric Rose, SIGA’s Chief Executive Officer. Dr. Rose further noted that “this trial advances our efforts to ensure better protection of Americans from a smallpox outbreak.”

Previous laboratory and animal tests suggest that tecovirimat blocks the ability of the virus to spread, thus preventing disease symptoms in animal models of smallpox in which tecovirimat has been tested to date. Laboratory experiments also suggest that tecovirimat may function without compromising acquisition of protective immunity.

Source: SIGA Technologies press release, adapted.

From Our Partners
Tags: Animal ModelsASPRBARDAHHSSmallpox

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies
Biosecurity

Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies

June 14, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Load More

Latest News

Biodefense Headlines – 5 July 2022

Biodefense Headlines – 5 July 2022

July 5, 2022
Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC